Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NT5E | P21589 | 2/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DCK | P27707 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881298 | 1.00 | POLB (0.38) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL16639153 | 1.00 | POLB (0.38) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL3621139 | 1.00 | POLB (0.38) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL3654823 | 1.00 | POLB (0.38) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL13881205 | 0.93 | LMNA (0.36) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL13881206 | 0.93 | LMNA (0.36) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL13881517 | 0.89 | ABL1 (0.41) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL13881207 | 0.89 | ABL1 (0.41) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL12995180 | 0.87 | LMNA (0.35) | POLBABL1RIN1LMNAKMT2A | |
| SCHEMBL13881305 | 0.87 | LMNA (0.35) | POLBABL1RIN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190839-B1 | A PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | AVEXA LTD (AU) | 2015-04-15 | — | — | EP | disclosed |
| EP-2190839-B1 | A PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | AVEXA LTD (AU) | 2015-04-15 | — | — | EP | disclosed |
| US-8318934-B2 | Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-8318934-B2 | Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-20100305321-A1 | PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | AVEXA LIMITED (AU) | 2010-12-02 | — | — | US | disclosed |
| US-20100305321-A1 | PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | AVEXA LIMITED (AU) | 2010-12-02 | — | — | US | disclosed |
| EP-2190839-A1 | A PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | Avexa Limited (AU) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009039582-A1 | A PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | AVEXA LIMITED (AU) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009039582-A1 | A PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | AVEXA LIMITED (AU) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305321-A1 | PROCESS FOR CHIRAL RESOLUTION OF 2-SUBSTITUTED 4-SUBSTITUTED 1,3-OXATHIOLANES | DHPS, ICMT, ORC3 | POLB 1817/4885ABL1 3228/4885RIN1 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.